These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 10889864)

  • 41. Genetic susceptibility for breast cancer: testing and primary prevention options.
    Baron RH; Borgen PI
    Oncol Nurs Forum; 1997 Apr; 24(3):461-8. PubMed ID: 9127359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Genetic counselling in male carriers of BRCA1 and BRCA2 gene mutations].
    Plevová P; Hladíková A
    Klin Onkol; 2012; 25 Suppl():S67-73. PubMed ID: 22920210
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers.
    Eeles RA
    Breast Cancer Res; 2000; 2(4):283-90. PubMed ID: 11250722
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hereditary breast cancer risk: factors associated with the decision to undergo BRCA 1 testing.
    Gil F
    Eur J Cancer Prev; 1996 Dec; 5(6):488-90. PubMed ID: 9061281
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Familial non-BRCA1/BRCA2-associated breast cancer.
    Eccles DM; Pichert G
    Lancet Oncol; 2005 Sep; 6(9):705-11. PubMed ID: 16129371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
    Krassuski L; Vennedey V; Stock S; Kautz-Freimuth S
    BMC Med Inform Decis Mak; 2019 Aug; 19(1):154. PubMed ID: 31370837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of lifestyle intervention in BRCA1/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): study protocol for a randomized controlled trial.
    Kiechle M; Engel C; Berling A; Hebestreit K; Bischoff SC; Dukatz R; Siniatchkin M; Pfeifer K; Grill S; Yahiaoui-Doktor M; Kirsch E; Niederberger U; Enders U; Löffler M; Meindl A; Rhiem K; Schmutzler R; Erickson N; Halle M
    Trials; 2016 Jul; 17():368. PubMed ID: 27473440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching.
    Hallowell N; Foster C; Ardern-Jones A; Eeles R; Murday V; Watson M
    Genet Test; 2002; 6(2):79-87. PubMed ID: 12215246
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
    Roed Nielsen H; Petersen J; Therkildsen C; Skytte AB; Nilbert M
    Acta Oncol; 2016; 55(1):38-44. PubMed ID: 26360800
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical value of gene diagnosis in breast cancer].
    Iwase H
    Rinsho Byori; 1998 Sep; 46(9):869-75. PubMed ID: 9800471
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Diagnostic molecular biology in breast cancer].
    Andersen TI; Børresen-Dale AL
    Tidsskr Nor Laegeforen; 1998 Jun; 118(15):2366-9. PubMed ID: 9691806
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Care of hereditary breast cancer].
    Lin PC; Wang RH
    Hu Li Za Zhi; 2011 Apr; 58(2):81-6. PubMed ID: 21455897
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic predisposition to breast cancer: a surgical perspective.
    Sakorafas GH; Tsiotou AG
    Br J Surg; 2000 Feb; 87(2):149-62. PubMed ID: 10671920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Do physicians discuss genetic testing with family-history-positive breast cancer patients?
    Polednak AP
    Conn Med; 1998 Jan; 62(1):3-7. PubMed ID: 9509706
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer genetics for the clinician: recommendations on screening for BRCA1 and BRCA2 mutations.
    Clark BA
    Cleve Clin J Med; 2000 Jun; 67(6):408-15,. PubMed ID: 10860223
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Managing hereditary breast cancer risk in women with and without ovarian cancer.
    Peters ML; Garber JE; Tung N
    Gynecol Oncol; 2017 Jul; 146(1):205-214. PubMed ID: 28454658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Breast conservation in BRCA1 or BRCA2 mutation carriers with early stage breast cancer.
    Phillips KA; McKay MJ
    Australas Radiol; 2001 May; 45(2):200-4. PubMed ID: 11380364
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2.
    Jernström H; Lerman C; Ghadirian P; Lynch HT; Weber B; Garber J; Daly M; Olopade OI; Foulkes WD; Warner E; Brunet JS; Narod SA
    Lancet; 1999 Nov; 354(9193):1846-50. PubMed ID: 10584720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.
    Liede A; Mansfield CA; Metcalfe KA; Price MA; ; Snyder C; Lynch HT; Friedman S; Amelio J; Posner J; Narod SA; Lindeman GJ; Evans DG
    Breast Cancer Res Treat; 2017 Sep; 165(2):433-444. PubMed ID: 28624978
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
    Lecarpentier J; Silvestri V; Kuchenbaecker KB; Barrowdale D; Dennis J; McGuffog L; Soucy P; Leslie G; Rizzolo P; Navazio AS; Valentini V; Zelli V; Lee A; Amin Al Olama A; Tyrer JP; Southey M; John EM; Conner TA; Goldgar DE; Buys SS; Janavicius R; Steele L; Ding YC; Neuhausen SL; Hansen TVO; Osorio A; Weitzel JN; Toss A; Medici V; Cortesi L; Zanna I; Palli D; Radice P; Manoukian S; Peissel B; Azzollini J; Viel A; Cini G; Damante G; Tommasi S; Peterlongo P; Fostira F; Hamann U; Evans DG; Henderson A; Brewer C; Eccles D; Cook J; Ong KR; Walker L; Side LE; Porteous ME; Davidson R; Hodgson S; Frost D; Adlard J; Izatt L; Eeles R; Ellis S; Tischkowitz M; ; Godwin AK; Meindl A; Gehrig A; Dworniczak B; Sutter C; Engel C; Niederacher D; Steinemann D; Hahnen E; Hauke J; Rhiem K; Kast K; Arnold N; Ditsch N; Wang-Gohrke S; Wappenschmidt B; Wand D; Lasset C; Stoppa-Lyonnet D; Belotti M; Damiola F; Barjhoux L; Mazoyer S; ; Van Heetvelde M; Poppe B; De Leeneer K; Claes KBM; de la Hoya M; Garcia-Barberan V; Caldes T; Perez Segura P; Kiiski JI; Aittomäki K; Khan S; Nevanlinna H; van Asperen CJ; ; Vaszko T; Kasler M; Olah E; Balmaña J; Gutiérrez-Enríquez S; Diez O; Teulé A; Izquierdo A; Darder E; Brunet J; Del Valle J; Feliubadalo L; Pujana MA; Lazaro C; Arason A; Agnarsson BA; Johannsson OT; Barkardottir RB; Alducci E; Tognazzo S; Montagna M; Teixeira MR; Pinto P; Spurdle AB; Holland H; ; Lee JW; Lee MH; Lee J; Kim SW; Kang E; Kim Z; Sharma P; Rebbeck TR; Vijai J; Robson M; Lincoln A; Musinsky J; Gaddam P; Tan YY; Berger A; Singer CF; Loud JT; Greene MH; Mulligan AM; Glendon G; Andrulis IL; Toland AE; Senter L; Bojesen A; Nielsen HR; Skytte AB; Sunde L; Jensen UB; Pedersen IS; Krogh L; Kruse TA; Caligo MA; Yoon SY; Teo SH; von Wachenfeldt A; Huo D; Nielsen SM; Olopade OI; Nathanson KL; Domchek SM; Lorenchick C; Jankowitz RC; Campbell I; James P; Mitchell G; Orr N; Park SK; Thomassen M; Offit K; Couch FJ; Simard J; Easton DF; Chenevix-Trench G; Schmutzler RK; Antoniou AC; Ottini L
    J Clin Oncol; 2017 Jul; 35(20):2240-2250. PubMed ID: 28448241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.